Palau's Initiative to Schedule Nicotine under the UN Convention on Psychotropic Substances (1971)

Situation summary

The Republic of Palau has submitted a formal notification under Article 2 of the 1971 UN Convention on Psychotropic Substances, triggering a critical review of nicotine by the WHO Expert Committee on Drug Dependence (ECDD), its first review of nicotine since the mid-1990s. The review process begins in late 2026, with the Committee's critical-review recommendation expected at its 50th meeting in October 2027. That recommendation goes to the Commission on Narcotic Drugs (CND), a rotating 53-member body that votes on scheduling by a two-thirds majority; the vote is targeted for March 2028, five months after the ECDD recommendation.

The notification is accompanied by a coordinated campaign run by an international coalition of tobacco-control organisations (Action on Smoking and Health, the European Network for Smoking and Tobacco Prevention, Doctors Against Tobacco and others), which since June 2026 has been actively approaching further governments with requests to file parallel notifications, working to an informal campaign deadline of 31 August 2026. This is not a treaty deadline but a political instrument intended to project an impression of broader international support ahead of the ECDD's review process, which is expected to conclude with a recommendation in October 2027. The Czech Republic should expect that such an approach may arrive directly at the Ministry of Health or at an embassy over the summer, substantially earlier than October.

The declared aim of the initiative is to place nicotine as a molecule, across all current and future delivery forms, under strict international control, with an exemption for approved therapeutic products (patches, gums, inhalers). Outside that exemption, the sale of nicotine would fall under prescription-based pharmaceutical distribution.

The decisive question, however, is which products such a regime would actually cover. The 1971 Convention controls molecules, not plants. Cathinone and cathine, the active alkaloids of khat, are listed in Schedules I and III, but khat leaves themselves are not under international control, and the WHO confirmed this again in 2006. Psilocybin is likewise controlled, but not the mushrooms that contain it. Mescaline, but not peyote. DMT, but not ayahuasca. Plants are controlled only where they are explicitly named — cannabis, coca, opium poppy — and then under an entirely different instrument, the 1961 Convention. Palau has chosen the 1971 one.

The likely scenario is therefore not a full ban on nicotine in all its forms, although that cannot be entirely ruled out. Such an outcome would mean criminalising more than a billion people and the tobacco supply chains of China, India, the EU and the United States, and no one will assemble a two-thirds majority in the CND for it. What is realistically at stake is a far less conspicuous variant: control would apply to nicotine only in extracted or synthetic form (e-liquids, pouches, refills) while cigarettes, cigars and the tobacco leaf would remain entirely outside it, under the FCTC. The campaign's own organisers point towards this construction when they speak of a molecule-based layer of control alongside existing product-based regulation.

The risks of this variant are fundamental and at the same time easy to overlook. Above all, it faces no strong opposition: excise revenue from cigarettes remains untouched, and certain countries and monopolies would stand to benefit. Beyond that, the roughly forty countries that have already banned e-cigarettes — India, Brazil, Mexico, Thailand, Türkiye and others — form a ready-made voting core. The outcome would, in our view, be the exact opposite of what the campaign claims to seek: the deadliest product stays on sale in every tobacconist's, while products carrying an order of magnitude less risk end up under a strict international control schedule. And because scheduling automatically activates the 1988 Convention against illicit traffic, the full apparatus of drug enforcement would come down on a segment where the illicit share already exceeds three quarters of global volume.

The Czech Republic has no position on the matter. We recommend formulating one immediately rather than in reaction to the CND vote. Real influence is exercised at the level of the ECDD's scientific review, that is, in autumn 2027. Constructing it so that it addresses both scenarios, because the one more likely to pass is also the one that would do greater damage to the Czech market and to Czech drug policy.

Substantive analysis of the notification

Palau's motivation is understandable and evidenced: 21% of adults in the country smoked in 2023 and 46% of young people used e-cigarettes in 2022, while the 2023 ban on vapes did not resolve the problem. The request is in large part a response to frustration at a regulatory gap into which new nicotine products moved faster than legislation could react.

What matters, however, is to distinguish nicotine as a molecule from tobacco as a product. A recent Royal College of Physicians report states that nicotine itself presents little risk to health; the dominant harm arises from inhalation during the combustion of tobacco, not from nicotine as such. A Cochrane review further shows that users who switch to vaping are roughly twice as likely to succeed in quitting smoking. The cardiovascular risks Palau cites in its submission are precisely the data that the RCP and Cochrane contextualise as marginal relative to smoking, not an argument against that contextualisation.

The campaign's central message is not child protection, although it is communicated that way, but a specific regulatory thesis: that product by product regulation (cigarettes, vapes, pouches and heated tobacco treated separately) is structurally ineffective because consumers move freely between categories, and that the solution is to regulate the nicotine molecule itself across all delivery forms. This thesis blurs the distinction between nicotine dependence and smoking-related mortality by design. The same methodological problem set out above in relation to the RCP and Cochrane, not an independent observation but the same simplification, one that the campaign's own organisers acknowledge when they characterise the harm-reduction argument as an inadequate acceptance of addiction rather than as a legitimate public-health position.

The 1971 Convention's classification criteria (abuse potential and absence of therapeutic value) contain no comparative-harm variable. This is a methodological weakness in the notification and at the same time the core of the wider debate, well summarised in recent Guardian commentary: is dependence alone, absent any further demonstrated health impact, sufficient grounds to control a substance? An affirmative answer would in principle apply to other substances with a comparable dependence profile but a low harm profile.

This also forecloses one specific outcome. Because nicotine has recognised therapeutic value (approved NRT), the Convention's own criteria rule out placing it in Schedule I, the tier reserved for substances with no accepted medical use (MDMA, LSD, psilocybin). Schedule I also carries no mechanism for exempting approved preparations from control; that route (Article 3(3)) applies only to Schedules II–IV. Any WHO recommendation to control nicotine would therefore have to sit in a lower schedule, one that both accommodates its recognised medical use and allows preparation-level exemptions. Counterintuitively, this makes the “extracted and synthetic nicotine only” scenario described above more legally plausible, not less: it is the only construction consistent with the Convention's own schedule architecture.

Precedent risk for the harm-reduction framework

Classifying nicotine as a high-risk controlled substance would in practice equalise the regulatory status of products demonstrably less risky than smoking (vapes, pouches) with smoking itself, or worse. This is the exact opposite of the harm-reduction logic we advocate elsewhere, whether in drug checking at festivals or in our opposition to a generic scheduling approach to cannabinoids under the lex kratom.

The 2020 rescheduling of cannabis shows that the Convention can respond to evidence, but the process took decades and was heavily politicised. A classification logic established via nicotine, namely that dependence potential alone suffices for control regardless of relative harm, could subsequently be turned against other harm-reduction instruments well beyond nicotine itself.

It is worth noting that discussion of illicit-market risks appears to have been only marginal at the organisers' campaign webinar, which confirms that the argument about illicit-market formation is not being rebutted by proponents of the initiative so much as left unaddressed.

Recommendations for the Czech position

• Do not take a position of public support for a ban, nor position the country as a defender of the nicotine industry. The Czech Republic should articulate that the classification of controlled substances must proceed from differentiated, comparative harm, not from a binary criterion of the presence of dependence potential.
• Support not only the retention but the possible broadening of the medical exemption beyond approved NRT products, towards an evidence-based framework for low-risk products generally.
• Reject explicitly the asymmetric variant that would exempt the tobacco leaf while scheduling extracted and synthetic nicotine. This is politically the more passable of the two scenarios and, for the Czech Republic, the more damaging: it would leave the highest-mortality product freely available while pushing lower-risk products into a control regime and an illicit market.
• Coordinate the position with like-minded CND members ahead of the ECDD session in October 2027, since real influence is exercised at the level of the scientific review, not at the vote in 2028.
• Decline any offer to co-sign a parallel notification, regardless of how the procedural neutrality of the request is framed (“this is only a scientific review, not support for a ban”).
• Consider a public statement by the Ministry of Health framing the question as one of scientific classification methodology, not as support for or opposition to a nicotine ban as such.
• Consider the potential impact on the development of illicit markets in future, having regard to current growth trends in the still-regulated environment for the sale of nicotine products.
• Consider obtaining a position from Czech security and intelligence services on the future security implications of illicit markets and incorporate it into the national position under preparation.